ELVN NASDAQ
Enliven Therapeutics, Inc.
1W: +7.2%
1M: -7.3%
3M: -22.8%
YTD: +167.0%
1Y: +101.9%
3Y: +226.9%
5Y: +175.9%
$43.69
+2.20 (+5.30%)
After Hours: $43.28 (-0.41, -0.93%)
Weekly Expected Move ±6.8%
$36
$39
$42
$44
$47
Credit Risk of going bust: lower than 83% of companies Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down more than 99.9%), Enliven Therapeutics, Inc. would be worth roughly what it owes.
Total debt $1.5M against a stock market value of $3.04B.
Distance to default 10.59 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $1.1M (short-term plus half of long-term), stock volatility 73.1%; Altman Z'' 66.56. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.00 (down more than 99.9%), Enliven Therapeutics, Inc. would be worth roughly what it owes.
Total debt $1.5M against a stock market value of $3.04B.
Distance to default 10.59 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $1.1M (short-term plus half of long-term), stock volatility 73.1%; Altman Z'' 66.56. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.00
Neutral
0 bullish
1 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (91)
Brokers Issue Forecasts for ELVN FY2027 Earnings
Enliven, FDA agree on phase 3 trial design for relcobatinib for chronic myeloid leukemia
Enliven Therapeutics (NASDAQ:ELVN) Stock Falls 4.5% Following Insider Selling
Enliven Therapeutics (NASDAQ:ELVN) Director J. Scott Garland Sells 13,000 Shares of Company Stock
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Average Recommendation of “Moderate Buy” from Brokerages
These ten healthcare stocks posted the biggest one-month losses
10 mid-cap healthcare stocks with the strongest momentum grades
These mid-cap stocks have A+ momentum grades and over 100% YTD growth
Bank of New York Mellon Corp Purchases New Position in Enliven Therapeutics, Inc. $ELVN
Bank of America Corp DE Grows Stock Position in Enliven Therapeutics, Inc. $ELVN
Algert Global LLC Makes New Investment in Enliven Therapeutics, Inc. $ELVN
BlackRock Inc. Invests $221.25 Million in Enliven Therapeutics, Inc. $ELVN
Dimensional Fund Advisors LP Raises Holdings in Enliven Therapeutics, Inc. $ELVN
Enliven Therapeutics, Inc. $ELVN is Avidity Partners Management LP’s 6th Largest Position
What to Know About This $345,000 Enliven Insider Sale as the Stock Soars 130%
What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rally
Medical Hedge Fund Sells 281,000 Shares of Enliven Theapeutics. Is it Time to Sell ELVN?
Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Responsive Playbooks and the ELVN Inflection - Stock Traders Daily
Enliven Therapeutics (ELVN) Soars on Stellar Leukemia Drug Trial
ELVN Stock Jumps As FDA-Cleared Path Fuels Phase 3 Push - timothysykes.com
Enliven Therapeutics (Nasdaq: ELVN) plans $400M stock and warrant sale - Stock Titan
Enliven Therapeutics (NASDAQ: ELVN) raises $376M via 8.93M-share offering - Stock Titan
ELVN Stock On Track For Best Week Since March Following FDA-Aligned Path For Cancer Drug Development
ELVN Stock On Track For Best Week Since March Following FDA-Aligned Path For Cancer Drug Development - TradingView
Enliven Therapeutics Stock Surges On ELVN-001 Breakthrough And $400M Raise - StocksToTrade
ELVN Stock Jumps As FDA Clears Path For Phase 3 ENABLE Trial - StocksToTrade
Enliven Therapeutics (ELVN) Stock Surges On FDA, Trial Wins - timothysykes.com
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Friday Ahead of SpaceX Debut
Enliven Therapeutics prices upsized $400M public offering of common stock and pre-funded warrants
Biotech Enliven prices ~$400 million stock and warrant sale - Stock Titan
Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants - PR Newswire
Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - PR Newswire
Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
ELVN Stock Pops As Wall Street Targets Phase 3 Catalyst - StocksToTrade
ELVN Stock Jumps As Analysts Hike Price Targets - StocksToTrade
Crude Oil Edges Higher; Driven Brands Posts Upbeat Earnings
ELVN Stock Pops As Analysts Hike Biotech Price Targets - timothysykes.com
$ELVN stock is up 13% today. Here's what we see in our data. - Quiver Quantitative
Enliven Therapeutics Reports Positive Phase 1 CML Data and FDA Alignment for Phase 3 Trial (ELVN)
Stitch Fix, Intel, KLA And Other Big Stocks Moving Higher On Thursday
Enliven Therapeutics Says Aligned With US FDA on Dose Recommendation for Late-Stage Chronic Myeloid Leukemia Trial
Enliven (NASDAQ: ELVN) shares updated ELVN-001 CML data and FDA Phase 3 alignment - Stock Titan
Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components
CML drug ELVN-001 hits 61% major molecular response as FDA agrees on Phase 3 - Stock Titan
J&J looks to widen Imaavy’s use; $300M backs rare disease drug launch
Shareholders of Enliven (NASDAQ: ELVN) back 200M share increase - Stock Titan
Enliven (NASDAQ: ELVN) director sells 10,000 shares via 10b5-1 plan - Stock Titan
Toll Brothers upgraded, Lennar downgraded: Wall Street's top analyst calls
This Grand Canyon Education Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday
New Analyst Forecast: $ELVN Given $60 Price Target - Quiver Quantitative
A Look At Enliven Therapeutics (ELVN) Valuation As ENABLE Trial Data Update Nears
Enliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress
Enliven Therapeutics' Chief Medical Officer Sold 5,000 Company Shares. Here's What That Means for Investors.
Enliven Therapeutics' Chief Medical Officer Sold 5,000 Company Shares. Here's What That Means for Investors.
This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter
Enliven Therapeutics to Present at Upcoming Investor Conferences
Why This Biotech Fund Added $7 Million to an Oncology Stock Up 120%
Why This Biotech Fund Added $7 Million to an Oncology Stock Up 120%
Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML
Why is Enliven Therapeutics (ELVN) One of the Best Performing Healthcare Stocks so Far in 2026?
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
Enliven Therapeutics (NASDAQ:ELVN) Hits New 12-Month High – What’s Next?
Enliven Therapeutics (ELVN) Up 194% This Year on Strong CML Market
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Tango Therapeutics is the best performing healthcare stock in March
Q1 EPS Estimate for Enliven Therapeutics Reduced by Analyst
Enliven Theraeutics' (ELVN) Chief Medical Officer Sold 40,000 Shares for $1.2 Million
Enliven Therapeutics (NASDAQ:ELVN) Shares Gap Up Following Analyst Upgrade
Enliven Therapeutics (NASDAQ:ELVN) Hits New 12-Month High on Analyst Upgrade
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Enliven Therapeutics (NASDAQ:ELVN) Reaches New 1-Year High – Here’s Why
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives $41.00 Consensus PT from Analysts
Enliven Therapeutics: Q4 Earnings Insights
Enliven Therapeutics GAAP EPS of -$0.48 misses by $0.09
Enliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
Heron Therapeutics (NASDAQ:HRTX) & Enliven Therapeutics (NASDAQ:ELVN) Head to Head Contrast
Enliven Therapeutics Chief Scientific Officer Sells ELVN 20K Shares Worth Over $500k
Joseph Lyssikatos Sells 20,000 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock
Anish Patel Sells 48,300 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock
Enliven Therapeutics Early Leukemia Drug Results Impress, Stock Soars
Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones
Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Average Rating of “Moderate Buy” from Brokerages
Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
Enliven Therapeutics Announces New CEO to Drive Next Phase of Development
Wall Street Analysts Believe Enliven Therapeutics, Inc. (ELVN) Could Rally 101.26%: Here's is How to Trade